Sources

8 Total Sources

Survodutide Cuts Liver Fat in 84% of Phase 3 MASLD Patients as Weight Falls 12.2%

Center100%

Nature.com1d ago

Survodutide Phase 3 Trial Shows Significant Reductions in Liver Fat and Body Weight for Obesity, MASLD

boehringer-ingelheim.com1d ago

survodutide-phase-3-fat-loss-obesity-dual-agonist-data | Boehringer Ingelheim

investorshangout.com1d ago

Survodutide's Promise: Tackling Obesity and Liver Health - Investors Hangout

linkedin21h ago

New Data from ADA 2026: Survodutide Demonstrates Broad Benefits Across Weight, Metabolic Health, and Liver Disease in At-Risk MASLD One of the most interesting presentations at ADA 2026 was… | Fatty Liver Alliance

clinicaltrialvanguard.com9h ago

Survodutide Phase III trial shows 34% visceral fat, 63% liver fat reduction

AJMC.com Managed Markets Network1d ago

Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD

MD Magazine1d ago

Survodutide Shows Fat Mass Loss, Liver Fat Reductions in Patients With Obesity Without T2D | HCPLive

Fierce Biotech1d ago

ADA: Tolerability questions linger for Boehringer's obesity drug